股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 長江生命科技集團有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00775 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 15,000,000,000 | | HKD | | 0.1 HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 15,000,000,000 | HKD | | 0.1 HKD | | 1,500,000,000 | FF301 II. 已發 ...

（於開曼群島註冊成立的有限公司） （股份代號：0775） 二零二五年度中期報告 提升 健康生活 此 二 零 二 五 年 度 中 期 報 告（ 英 文 版 及 中 文 版 ）（「 中 期 報 告 」）已 於 本 公 司 網 站 （https://www.ck-lifesciences.com）及香港交易及結算所有限公司網站（https://www.hkexnews.hk） 登載。 股東如欲收取本公司之公司通訊（包括但不限於中期報告）印刷本，謹請按照本公司網站「投資 者關係」下「發佈公司通訊」欄目內之指示填妥相關要求表格，並將填妥之表格交回本公司股份 登記分處香港中央證券登記有限公司。 股東之任何該等要求將於一年後失效。然而，倘於原有要求失效日期前，股東書面撤回原有 要求或提出後續書面要求取代原有要求，原有要求將更早失效。股東如欲於原有要求失效後 繼續收取公司通訊印刷本，股東必須交回一份填妥之新要求表格。 股東可隨時透過本公司股份登記分處以電郵（至cklife.ecom@computershare.com.hk）或郵寄（至 香港皇后大道東183號合和中心17M樓）方式預先給予本公司合理時間的書面通知，以更改其 收 ...

Core Insights - Changjiang Life Science Technology (00775) reported a revenue of HKD 2.606 billion for the first half of 2025, representing a year-on-year decrease of 1.14% [1] - The company recorded a loss attributable to shareholders of HKD 150 million, compared to a profit of HKD 1.001 million in the same period last year [1] - The loss per share was HKD 0.0157 [1] Financial Performance - Revenue for the first half of 2025 was HKD 2.606 billion, down from the previous year [1] - The company shifted from profit to loss, primarily due to an increase in research and development investment [1] - R&D expenses rose significantly from HKD 72.9 million in 2024 to HKD 235.3 million in 2025, an increase of HKD 162.4 million [1]

Core Viewpoint - Changjiang Life Science Technology (00775) reported a revenue of HKD 2.606 billion for the first half of 2025, representing a year-on-year decrease of 1.14% [1] - The company recorded a loss attributable to shareholders of HKD 150 million, compared to a profit of HKD 1.001 million in the same period last year, resulting in a loss per share of HKD 0.0157 [1] Financial Performance - Revenue for the first half of 2025 was HKD 2.606 billion, down 1.14% from the previous year [1] - The company experienced a shift from profit to loss, with a loss of HKD 150 million compared to a profit of HKD 1.001 million in the same period last year [1] - Loss per share was reported at HKD 0.0157 [1] Research and Development Investment - The company increased its R&D investment from HKD 72.9 million in 2024 to HKD 235.3 million in 2025, an increase of HKD 162.4 million [1] - This increase in R&D spending is aimed at accelerating the company's research projects [1]

(於開曼群島註冊成立之有限公司) (股份代號：0775) 二零二五年中期業績 二零二五年中期業績 - 增加研發投資 截至二零二五年六月三十日止六個月，長江生命科技集團有限公司（「長江生命 科技」或「公司」）錄得未經審核股東應佔虧損約港幣一億五千零八十萬元，相 較去年同期之股東應佔溢利港幣一百萬元，負差異為港幣一億五千一百八十萬元。 二零二四年上半年度與二零二五年同期比較由盈轉虧，乃歸因於公司早前 計劃增加研發投資之決定，相關款項由二零二四年之港幣七千二百九十萬元 提升至二零二五年的港幣二億三千五百三十萬元，亦即公司增加投入 港幣一億六千二百四十萬元於科研項目以加快進程。 根據公司保守之會計政策，各項研發投資於產生期間以費用入賬處理。 如二零二五年上半年度的科研開支與去年相同，期內錄得之淨溢利貢獻會較 二零二四年同期略增（增幅為港幣一千零六十萬元）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本文件的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本文件全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 董事會宣佈不派發二零二五年度中期股息（二零二四年：無） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 長江生命科技集團有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00775 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 9,611,072,400 | | 0 | | 9,611,072,400 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 9,611,072,400 | | 0 | | 9,611,072,400 | 第 2 頁 共 10 頁 v 1.1.1 ...

消息面上，7月31日，长江生命科技发布公告，集团预期截至2025年6月30日止六个月取得约港币1.5亿 元股东应占亏损，对比2024年同期，股东应占溢利为港币100万元。是次应占溢利转盈为亏乃归因于公 司早前计划增加研发投资的决定。整体而言，集团的营运于报告期间及截至本公告日期一直维持稳定。 本文源自智通财经网 港股异动｜长江生命科技(00775)盈警后跌超5% 预计中期取得股东应占亏损约1.5亿港元 金融界 智通财经获悉，长江生命科技(00775)盈警后跌超5%，截至发稿，跌5%，报0.95港元，成交额574.89万 港元。 ...

Group 1 - The core viewpoint of the article is that Changjiang Life Science Technology (00775) issued a profit warning, leading to a decline of over 5% in its stock price, currently trading at HKD 0.95 with a transaction volume of HKD 5.7489 million [1] - The company anticipates a shareholder loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a profit of HKD 1 million in the same period of 2024 [1] - The shift from profit to loss is attributed to the company's earlier decision to increase research and development investments [1] Group 2 - Overall, the company's operations have remained stable during the reporting period and up to the date of the announcement [1]

Core Viewpoint - Changjiang Life Science Technology (00775) issued a profit warning, leading to a decline of over 5% in its stock price, currently trading at HKD 0.95 with a trading volume of HKD 5.7489 million [1] Financial Performance - The company expects to report a shareholder loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a shareholder profit of HKD 1 million for the same period in 2024 [1] - The shift from profit to loss is attributed to the company's earlier decision to increase research and development investments [1] Operational Stability - Overall, the company's operations have remained stable during the reporting period and up to the date of the announcement [1]

Performance Updates - 开拓药业-B (09939.HK) has completed patient enrollment for the Phase III clinical trial of KX-826 solution for androgenetic alopecia in adult males in China [2] - 李氏大药厂 (00950.HK) has received approval from the National Medical Products Administration for Socazolimab to be used in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer in mainland China [2] - 恒瑞医药 (01276.HK) has received approval for clinical trials of SHR-8068 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [2] - 恒瑞医药 (01276.HK) has also received approval to conduct clinical trials for HRS-5041, intended for prostate cancer treatment [2] - 深圳高速公路股份 (00548.HK) reported toll revenue of 106 million yuan for the outer ring project in June [2] - 大成生化科技 (00809.HK) has signed an EPC contract with Northeast Electric and Liaoning Electric for boiler renovation projects, with a maximum cost of 129.1 million yuan [2] - 小黄鸭德盈 (02250.HK) has signed a contract to develop an AI marketing system to diversify revenue sources [2] Buyback and Financing Activities - 威海银行 (09677.HK) plans to issue up to approximately 758 million domestic shares and 154 million H-shares, raising nearly 3 billion yuan [2] Financial Results - 香港电讯-SS (06823.HK) reported total revenue of 17.322 billion HKD for the first half, a year-on-year increase of 4%, with a net profit of 2.07 billion HKD, also up 4% [4] - 青岛银行 (03866.HK) reported operating revenue of 7.662 billion yuan for the first half, a growth of 7.5%, and a net profit of 3.065 billion yuan, up 16.05% [4] - 中国石油化工股份 (00386.HK) expects mid-term net profit to be between 20.1 billion and 21.6 billion yuan, a year-on-year decline of 39.5%-43.7% [4] - 汽车之家-S (02518.HK) reported total revenue of 3.212 billion yuan for the first half, a decrease of 7.75%, with a net profit of 772 million yuan, down 15.99% [4] - 绿茶集团 (06831.HK) issued a profit warning, expecting mid-term net profit to be between 230 million and 237 million yuan, a year-on-year increase of approximately 32%-36% [4] - 粤海置地 (00124.HK) issued a profit warning, expecting mid-term net profit to exceed 260 million HKD, turning from loss to profit [4] - 药师帮 (09885.HK) issued a profit warning, expecting mid-term net profit to exceed 70 million yuan [4] - 中国东方教育 (00667.HK) issued a profit warning, expecting mid-term net profit to grow by 45%-50% year-on-year [4] - 中核国际 (02302.HK) issued a profit warning, expecting mid-term revenue to increase to at least 585 million HKD, with net profit of at least 9.5 million HKD [4] - 大唐环境 (01272.HK) issued a profit warning, expecting mid-term net profit to decrease to between 350 million and 400 million yuan [4] - 长江生命科技 (00775.HK) issued a profit warning, expecting mid-term net loss of approximately 150 million HKD, turning from profit to loss year-on-year [4] - 延长石油国际 (00346.HK) issued a profit warning, expecting mid-term loss of approximately 27.9 million HKD [4]